Daniel J. Blackman

Showing 1-7 of 7 articles

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation

Dobson L, Musa T, Uddin A, Fairbairn T, Swoboda P, Ripley D, Garg P, Evans B, Malkin C, Blackman D, Plein S, Greenwood J

June 2, 2017 | 10.4244/EIJ-D-16-00558

Interventions for valvular disease

Impact of left ventricular function and transaortic gradient on outcomes from transcatheter aortic valve implantation: data from the UK TAVI Registry

Malkin C, Long W, Baxter P, Gale C, Wendler O, Monaghan M, Thomas M, Ludman P, De Belder M, Cunningham A, Moat N, Blackman D

February 19, 2016 | 10.4244/EIJY14M12_12

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D

May 21, 2013 | 10.4244/EIJV9I1A17

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Kelly D, McCann G, Blackman D, Curzen N, Dalby M, Greenwood J, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan J, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick A

February 22, 2013 | 10.4244/EIJV8I10A183

Complications of transcatheter aortic valve implantation: avoidance and management

Hildick-Smith D, Redwood S, Mullen M, Thomas M, Kovac J, Brecker S, Trivedi U, Young C, Hutchinson N, MacCarthy P, Prendergast B, De Belder M, Monaghan M, Blackman D, Baumbach A, Manoharan G, Moat N

September 30, 2011 | 10.4244/EIJV7I5A99

Latest news

NEW ISSUE

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

AHEAD OF PRINT

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

AHEAD OF PRINT

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

EDITORIAL

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

EDITORIAL

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

EDITORIAL

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?